ADMA Biologics (NASDAQ:ADMA) Stock Price Target Raised at Cantor Fitzgerald

ADMA Biologics (NASDAQ:ADMA) had its target price hoisted by equities research analysts at Cantor Fitzgerald from $12.00 to $13.00 in a report released on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. Cantor Fitzgerald‘s price objective indicates a potential upside of 24.05% from the company’s current price.

Several other equities analysts also recently commented on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research note on Monday, September 14th. Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 2nd. Finally, Mizuho set a $18.00 price target on ADMA Biologics in a research report on Thursday. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.50.

ADMA Biologics Stock Performance

ADMA opened at $10.48 on Thursday. ADMA Biologics has a 1 year low of $7.21 and a 1 year high of $20.46. The company has a market capitalization of $2.35 billion, a PE ratio of 14.97 and a beta of 0.65. The business has a fifty day simple moving average of $10.07 and a 200 day simple moving average of $10.93. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.20 by $0.03. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The company had revenue of $141.10 million during the quarter, compared to analysts’ expectations of $138.11 million. During the same period in the previous year, the company earned $0.15 EPS. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. Research analysts expect that ADMA Biologics will post 0.78 EPS for the current year.

Institutional Trading of ADMA Biologics

Several institutional investors and hedge funds have recently made changes to their positions in ADMA. BlackRock Inc. purchased a new stake in ADMA Biologics in the second quarter valued at approximately $321,037,000. Nantahala Capital Management LLC acquired a new stake in ADMA Biologics in the 2nd quarter valued at $19,753,141. Ranger Investment Management L.P. acquired a new stake in ADMA Biologics in the 2nd quarter worth about $17,706,000. Bank of America Corp DE grew its holdings in shares of ADMA Biologics by 107.5% during the first quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock worth $36,019,000 after buying an additional 2,071,338 shares in the last quarter. Finally, Rubric Capital Management LP acquired a new position in shares of ADMA Biologics during the 1st quarter worth approximately $16,303,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics News Roundup

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA reported Q3 revenue of $141.1 million, up 5% year over year and above analyst estimates. GAAP EPS was $0.22 and adjusted EPS was $0.23, both ahead of consensus; net income and adjusted EBITDA also grew year over year. ADMA Biologics Q3 2026 results
• Positive Sentiment: ASCENIV revenue rose 31% to $124.7 million, while gross margin expanded to 71% from a year earlier—supporting the company’s growth and profitability story. ADMA Biologics Q3 2026 earnings
• Positive Sentiment: The company reiterated its 2026 revenue outlook of at least $530 million and raised its minimum adjusted EBITDA outlook to at least $275 million, citing accelerating ASCENIV demand. Higher expected earnings could support investor confidence. ADMA reiterates revenue outlook and raises EBITDA outlook
• Positive Sentiment: ADMA also cited encouraging FDA feedback on its SG-001 pre-IND package, alongside cash generation and share repurchases. These could offer additional support, though the pipeline program is earlier-stage. ADMA business update

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.